Latest Aromatase inhibitor Stories
A predictive measurement -- preoperative endocrine prognostic index, or PEPI score -- may help women choose breast cancer treatment, U.S. researchers said. Researchers led by Dr. Matthew Ellis of Washington University developed and validated the PEPI score.
By Liz Szabo Women who survive five years after being diagnosed with breast cancer have a good chance of remaining cancer-free, a new study shows.
ANN ARBOR, Mich., July 17 /PRNewswire/ -- Meditrina Pharmaceuticals, Inc.
Amgen has reported positive results from a three-year pivotal Phase III placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer.
SAN FRANCISCO and EMERYVILLE, Calif., June 16 /PRNewswire-FirstCall/ -- Bionovo Inc. today announced results from animal studies of its drug candidate, VG101.
Women whose breast cancer came back after treatment had almost twice as much estrogen in their blood than did women who remained cancer-free, despite treatment with anti-estrogen drugs in a majority of the women.
Being overweight in young adulthood or later in life may raise a woman's risk of ovarian cancer, particularly if she's never had children, researchers have found.
The osteoporosis drug Evista works as well as tamoxifen in reducing the risk of breast cancer in high-risk older women, with fewer dangerous side effects, researchers said on Monday.
By Martha Kerr NEW YORK (Reuters Health) - Chemotherapy with drugs called aromatase inhibitors is unnecessary after lumpectomy, radiation and 5 years of tamoxifen for the vast majority of women with breast cancer, researchers reported at the annual meeting of the American Society for Therapeutic Radiation and Oncology in Denver.
Why do estrogen-dependent breast-cancer cells grow and spread rapidly? Researchers at the University of Illinois at Urbana-Champaign say it may be because estrogen virtually eliminates levels of a vitally important regulatory protein.